Repeated immunosuppressive rabbit antithymocyte globulin therapy for adult patients with relapsed or refractory aplastic anemia
Objectives Immunosuppressive therapy (IST) with antithymocyte globulin (ATG) and cyclosporin A is the standard treatment for aplastic anemia (AA). However, the efficacy of repeated IST with rabbit ATG (rATG) as salvage therapy remains unclear in patients with relapsed or refractory AA. Methods We re...
Gespeichert in:
| Veröffentlicht in: | European journal of haematology 2023-11, Vol.111 (5), p.768-776 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 776 |
|---|---|
| container_issue | 5 |
| container_start_page | 768 |
| container_title | European journal of haematology |
| container_volume | 111 |
| creator | Sakamoto, Tatsuhiro Obara, Naoshi Maruyama, Yumiko Kato, Takayasu Kurita, Naoki Hattori, Keiichiro Suehara, Yasuhito Nishikii, Hidekazu Yokoyama, Yasuhisa Sakata‐Yanagimoto, Mamiko Usuki, Kensuke Chiba, Shigeru |
| description | Objectives
Immunosuppressive therapy (IST) with antithymocyte globulin (ATG) and cyclosporin A is the standard treatment for aplastic anemia (AA). However, the efficacy of repeated IST with rabbit ATG (rATG) as salvage therapy remains unclear in patients with relapsed or refractory AA.
Methods
We retrospectively evaluated the efficacy and safety of IST2 with rATG (IST2‐rATG) in 19 consecutive patients with relapsed or refractory AA who received first‐line IST with rATG in two centers between 2009 and 2020.
Results
The overall 6‐month response rate of the patients was 58%. The response rates were similar between patients with relapsed and refractory AA. The presence of glycophosphatidylinositol‐deficient blood cells was associated with a better response to IST2‐rATG. Despite retreatment with the same rATG, serum disease and severe allergic reactions were not observed.
Conclusion
IST2‐rATG is effective and safe for the treatment of adult patients with relapsed and refractory AA after receiving first‐line IST with rATG. |
| doi_str_mv | 10.1111/ejh.14075 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2847746623</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2847746623</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3135-b9cb8f510473e597ca22891769c75f9f7da37f3a56d1d05c16a77982c24f3b023</originalsourceid><addsrcrecordid>eNp1kU1rFTEUhoNY7LW68A9IwI0ups3nZLKUUq2lUBBdD5nMGW8umUlMMpZZ9a8bvdWF4NmcxXl4eA8vQq8oOad1LuCwP6eCKPkE7WhLSENaop-iHdGENUIIeoqe53wghDBN1TN0ypUUWnOxQw-fIYIpMGI3z-sS8hpjgpzdD8DJDIMr2CzFlf02B7sVwN98GFbvFlz2kEzc8BQSNuPqC46mOFhKxveVxwm8ibmK6z3BlIwtIW3YRG9ycbZqYXbmBTqZjM_w8nGfoa8frr5cXje3dx8_Xb6_bSynXDaDtkM3SUqE4iC1soaxrv7SaqvkpCc1Gq4mbmQ70pFIS1ujlO6YZWLiA2H8DL09emMK31fIpZ9dtuB9jRHW3LNOKCXalvGKvvkHPYQ1LTVdpRTpOs6JrNS7I2VTyLk-2MfkZpO2npL-Vyt9baX_3UplXz8a12GG8S_5p4YKXByBe-dh-7-pv7q5Pip_At9YmIQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2870883305</pqid></control><display><type>article</type><title>Repeated immunosuppressive rabbit antithymocyte globulin therapy for adult patients with relapsed or refractory aplastic anemia</title><source>Wiley Online Library All Journals</source><creator>Sakamoto, Tatsuhiro ; Obara, Naoshi ; Maruyama, Yumiko ; Kato, Takayasu ; Kurita, Naoki ; Hattori, Keiichiro ; Suehara, Yasuhito ; Nishikii, Hidekazu ; Yokoyama, Yasuhisa ; Sakata‐Yanagimoto, Mamiko ; Usuki, Kensuke ; Chiba, Shigeru</creator><creatorcontrib>Sakamoto, Tatsuhiro ; Obara, Naoshi ; Maruyama, Yumiko ; Kato, Takayasu ; Kurita, Naoki ; Hattori, Keiichiro ; Suehara, Yasuhito ; Nishikii, Hidekazu ; Yokoyama, Yasuhisa ; Sakata‐Yanagimoto, Mamiko ; Usuki, Kensuke ; Chiba, Shigeru</creatorcontrib><description>Objectives
Immunosuppressive therapy (IST) with antithymocyte globulin (ATG) and cyclosporin A is the standard treatment for aplastic anemia (AA). However, the efficacy of repeated IST with rabbit ATG (rATG) as salvage therapy remains unclear in patients with relapsed or refractory AA.
Methods
We retrospectively evaluated the efficacy and safety of IST2 with rATG (IST2‐rATG) in 19 consecutive patients with relapsed or refractory AA who received first‐line IST with rATG in two centers between 2009 and 2020.
Results
The overall 6‐month response rate of the patients was 58%. The response rates were similar between patients with relapsed and refractory AA. The presence of glycophosphatidylinositol‐deficient blood cells was associated with a better response to IST2‐rATG. Despite retreatment with the same rATG, serum disease and severe allergic reactions were not observed.
Conclusion
IST2‐rATG is effective and safe for the treatment of adult patients with relapsed and refractory AA after receiving first‐line IST with rATG.</description><identifier>ISSN: 0902-4441</identifier><identifier>EISSN: 1600-0609</identifier><identifier>DOI: 10.1111/ejh.14075</identifier><identifier>PMID: 37549934</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Anemia ; Antilymphocyte serum ; antithymocyte globulin ; Aplastic anemia ; Blood cells ; Cyclosporin A ; Globulins ; Glycosylphosphatidylinositol ; Hypersensitivity ; Immunosuppressive agents ; repeated IST ; salvage therapy ; Serum sickness ; Thymocytes</subject><ispartof>European journal of haematology, 2023-11, Vol.111 (5), p.768-776</ispartof><rights>2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3135-b9cb8f510473e597ca22891769c75f9f7da37f3a56d1d05c16a77982c24f3b023</cites><orcidid>0000-0001-7803-7338 ; 0000-0003-0366-4147 ; 0000-0002-1283-4307 ; 0000-0001-7310-8045 ; 0000-0001-6852-0721 ; 0000-0002-0914-7557 ; 0000-0002-0810-7887 ; 0000-0001-7046-2196 ; 0000-0001-6563-3093 ; 0000-0002-6277-4082 ; 0000-0002-1216-4470 ; 0000-0003-1410-0830</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fejh.14075$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fejh.14075$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37549934$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sakamoto, Tatsuhiro</creatorcontrib><creatorcontrib>Obara, Naoshi</creatorcontrib><creatorcontrib>Maruyama, Yumiko</creatorcontrib><creatorcontrib>Kato, Takayasu</creatorcontrib><creatorcontrib>Kurita, Naoki</creatorcontrib><creatorcontrib>Hattori, Keiichiro</creatorcontrib><creatorcontrib>Suehara, Yasuhito</creatorcontrib><creatorcontrib>Nishikii, Hidekazu</creatorcontrib><creatorcontrib>Yokoyama, Yasuhisa</creatorcontrib><creatorcontrib>Sakata‐Yanagimoto, Mamiko</creatorcontrib><creatorcontrib>Usuki, Kensuke</creatorcontrib><creatorcontrib>Chiba, Shigeru</creatorcontrib><title>Repeated immunosuppressive rabbit antithymocyte globulin therapy for adult patients with relapsed or refractory aplastic anemia</title><title>European journal of haematology</title><addtitle>Eur J Haematol</addtitle><description>Objectives
Immunosuppressive therapy (IST) with antithymocyte globulin (ATG) and cyclosporin A is the standard treatment for aplastic anemia (AA). However, the efficacy of repeated IST with rabbit ATG (rATG) as salvage therapy remains unclear in patients with relapsed or refractory AA.
Methods
We retrospectively evaluated the efficacy and safety of IST2 with rATG (IST2‐rATG) in 19 consecutive patients with relapsed or refractory AA who received first‐line IST with rATG in two centers between 2009 and 2020.
Results
The overall 6‐month response rate of the patients was 58%. The response rates were similar between patients with relapsed and refractory AA. The presence of glycophosphatidylinositol‐deficient blood cells was associated with a better response to IST2‐rATG. Despite retreatment with the same rATG, serum disease and severe allergic reactions were not observed.
Conclusion
IST2‐rATG is effective and safe for the treatment of adult patients with relapsed and refractory AA after receiving first‐line IST with rATG.</description><subject>Anemia</subject><subject>Antilymphocyte serum</subject><subject>antithymocyte globulin</subject><subject>Aplastic anemia</subject><subject>Blood cells</subject><subject>Cyclosporin A</subject><subject>Globulins</subject><subject>Glycosylphosphatidylinositol</subject><subject>Hypersensitivity</subject><subject>Immunosuppressive agents</subject><subject>repeated IST</subject><subject>salvage therapy</subject><subject>Serum sickness</subject><subject>Thymocytes</subject><issn>0902-4441</issn><issn>1600-0609</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp1kU1rFTEUhoNY7LW68A9IwI0ups3nZLKUUq2lUBBdD5nMGW8umUlMMpZZ9a8bvdWF4NmcxXl4eA8vQq8oOad1LuCwP6eCKPkE7WhLSENaop-iHdGENUIIeoqe53wghDBN1TN0ypUUWnOxQw-fIYIpMGI3z-sS8hpjgpzdD8DJDIMr2CzFlf02B7sVwN98GFbvFlz2kEzc8BQSNuPqC46mOFhKxveVxwm8ibmK6z3BlIwtIW3YRG9ycbZqYXbmBTqZjM_w8nGfoa8frr5cXje3dx8_Xb6_bSynXDaDtkM3SUqE4iC1soaxrv7SaqvkpCc1Gq4mbmQ70pFIS1ujlO6YZWLiA2H8DL09emMK31fIpZ9dtuB9jRHW3LNOKCXalvGKvvkHPYQ1LTVdpRTpOs6JrNS7I2VTyLk-2MfkZpO2npL-Vyt9baX_3UplXz8a12GG8S_5p4YKXByBe-dh-7-pv7q5Pip_At9YmIQ</recordid><startdate>202311</startdate><enddate>202311</enddate><creator>Sakamoto, Tatsuhiro</creator><creator>Obara, Naoshi</creator><creator>Maruyama, Yumiko</creator><creator>Kato, Takayasu</creator><creator>Kurita, Naoki</creator><creator>Hattori, Keiichiro</creator><creator>Suehara, Yasuhito</creator><creator>Nishikii, Hidekazu</creator><creator>Yokoyama, Yasuhisa</creator><creator>Sakata‐Yanagimoto, Mamiko</creator><creator>Usuki, Kensuke</creator><creator>Chiba, Shigeru</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QG</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>H94</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-7803-7338</orcidid><orcidid>https://orcid.org/0000-0003-0366-4147</orcidid><orcidid>https://orcid.org/0000-0002-1283-4307</orcidid><orcidid>https://orcid.org/0000-0001-7310-8045</orcidid><orcidid>https://orcid.org/0000-0001-6852-0721</orcidid><orcidid>https://orcid.org/0000-0002-0914-7557</orcidid><orcidid>https://orcid.org/0000-0002-0810-7887</orcidid><orcidid>https://orcid.org/0000-0001-7046-2196</orcidid><orcidid>https://orcid.org/0000-0001-6563-3093</orcidid><orcidid>https://orcid.org/0000-0002-6277-4082</orcidid><orcidid>https://orcid.org/0000-0002-1216-4470</orcidid><orcidid>https://orcid.org/0000-0003-1410-0830</orcidid></search><sort><creationdate>202311</creationdate><title>Repeated immunosuppressive rabbit antithymocyte globulin therapy for adult patients with relapsed or refractory aplastic anemia</title><author>Sakamoto, Tatsuhiro ; Obara, Naoshi ; Maruyama, Yumiko ; Kato, Takayasu ; Kurita, Naoki ; Hattori, Keiichiro ; Suehara, Yasuhito ; Nishikii, Hidekazu ; Yokoyama, Yasuhisa ; Sakata‐Yanagimoto, Mamiko ; Usuki, Kensuke ; Chiba, Shigeru</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3135-b9cb8f510473e597ca22891769c75f9f7da37f3a56d1d05c16a77982c24f3b023</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Anemia</topic><topic>Antilymphocyte serum</topic><topic>antithymocyte globulin</topic><topic>Aplastic anemia</topic><topic>Blood cells</topic><topic>Cyclosporin A</topic><topic>Globulins</topic><topic>Glycosylphosphatidylinositol</topic><topic>Hypersensitivity</topic><topic>Immunosuppressive agents</topic><topic>repeated IST</topic><topic>salvage therapy</topic><topic>Serum sickness</topic><topic>Thymocytes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sakamoto, Tatsuhiro</creatorcontrib><creatorcontrib>Obara, Naoshi</creatorcontrib><creatorcontrib>Maruyama, Yumiko</creatorcontrib><creatorcontrib>Kato, Takayasu</creatorcontrib><creatorcontrib>Kurita, Naoki</creatorcontrib><creatorcontrib>Hattori, Keiichiro</creatorcontrib><creatorcontrib>Suehara, Yasuhito</creatorcontrib><creatorcontrib>Nishikii, Hidekazu</creatorcontrib><creatorcontrib>Yokoyama, Yasuhisa</creatorcontrib><creatorcontrib>Sakata‐Yanagimoto, Mamiko</creatorcontrib><creatorcontrib>Usuki, Kensuke</creatorcontrib><creatorcontrib>Chiba, Shigeru</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Animal Behavior Abstracts</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sakamoto, Tatsuhiro</au><au>Obara, Naoshi</au><au>Maruyama, Yumiko</au><au>Kato, Takayasu</au><au>Kurita, Naoki</au><au>Hattori, Keiichiro</au><au>Suehara, Yasuhito</au><au>Nishikii, Hidekazu</au><au>Yokoyama, Yasuhisa</au><au>Sakata‐Yanagimoto, Mamiko</au><au>Usuki, Kensuke</au><au>Chiba, Shigeru</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Repeated immunosuppressive rabbit antithymocyte globulin therapy for adult patients with relapsed or refractory aplastic anemia</atitle><jtitle>European journal of haematology</jtitle><addtitle>Eur J Haematol</addtitle><date>2023-11</date><risdate>2023</risdate><volume>111</volume><issue>5</issue><spage>768</spage><epage>776</epage><pages>768-776</pages><issn>0902-4441</issn><eissn>1600-0609</eissn><abstract>Objectives
Immunosuppressive therapy (IST) with antithymocyte globulin (ATG) and cyclosporin A is the standard treatment for aplastic anemia (AA). However, the efficacy of repeated IST with rabbit ATG (rATG) as salvage therapy remains unclear in patients with relapsed or refractory AA.
Methods
We retrospectively evaluated the efficacy and safety of IST2 with rATG (IST2‐rATG) in 19 consecutive patients with relapsed or refractory AA who received first‐line IST with rATG in two centers between 2009 and 2020.
Results
The overall 6‐month response rate of the patients was 58%. The response rates were similar between patients with relapsed and refractory AA. The presence of glycophosphatidylinositol‐deficient blood cells was associated with a better response to IST2‐rATG. Despite retreatment with the same rATG, serum disease and severe allergic reactions were not observed.
Conclusion
IST2‐rATG is effective and safe for the treatment of adult patients with relapsed and refractory AA after receiving first‐line IST with rATG.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>37549934</pmid><doi>10.1111/ejh.14075</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-7803-7338</orcidid><orcidid>https://orcid.org/0000-0003-0366-4147</orcidid><orcidid>https://orcid.org/0000-0002-1283-4307</orcidid><orcidid>https://orcid.org/0000-0001-7310-8045</orcidid><orcidid>https://orcid.org/0000-0001-6852-0721</orcidid><orcidid>https://orcid.org/0000-0002-0914-7557</orcidid><orcidid>https://orcid.org/0000-0002-0810-7887</orcidid><orcidid>https://orcid.org/0000-0001-7046-2196</orcidid><orcidid>https://orcid.org/0000-0001-6563-3093</orcidid><orcidid>https://orcid.org/0000-0002-6277-4082</orcidid><orcidid>https://orcid.org/0000-0002-1216-4470</orcidid><orcidid>https://orcid.org/0000-0003-1410-0830</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0902-4441 |
| ispartof | European journal of haematology, 2023-11, Vol.111 (5), p.768-776 |
| issn | 0902-4441 1600-0609 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2847746623 |
| source | Wiley Online Library All Journals |
| subjects | Anemia Antilymphocyte serum antithymocyte globulin Aplastic anemia Blood cells Cyclosporin A Globulins Glycosylphosphatidylinositol Hypersensitivity Immunosuppressive agents repeated IST salvage therapy Serum sickness Thymocytes |
| title | Repeated immunosuppressive rabbit antithymocyte globulin therapy for adult patients with relapsed or refractory aplastic anemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T21%3A15%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Repeated%20immunosuppressive%20rabbit%20antithymocyte%20globulin%20therapy%20for%20adult%20patients%20with%20relapsed%20or%20refractory%20aplastic%20anemia&rft.jtitle=European%20journal%20of%20haematology&rft.au=Sakamoto,%20Tatsuhiro&rft.date=2023-11&rft.volume=111&rft.issue=5&rft.spage=768&rft.epage=776&rft.pages=768-776&rft.issn=0902-4441&rft.eissn=1600-0609&rft_id=info:doi/10.1111/ejh.14075&rft_dat=%3Cproquest_cross%3E2847746623%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2870883305&rft_id=info:pmid/37549934&rfr_iscdi=true |